Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Following a Reduced Intensity Conditioning Regimen by Fludarabine-treosulfan

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, we observed that Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse.
In this phase III randomised study, we propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.

Start Date01 Nov 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT05743400 / RecruitingPhase 4IIT

Thymoglobulin® Pharmacokinetics for Graft-versus Host Disease in Children and Adults Undergoing Hematopoietic Stem Cell Transplantation

Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human Leukocyte Antigen (HLA)-identical hematopoietic stem cell transplantations (HSCT), with a delicate balance between prevention of GvHD and the promotion of immune reconstitution. Thymoglobulin is known as a drug with high pharmacokinetic (PK) variability. This variability influences drug exposure, which in turn determines the drug response of pharmacodynamics (PD). In order to maintain efficacy while reducing adverse effects of drugs across the entire age range, identification of the PK/PD relationships and the effect of growth and maturation on the different PK and PD parameters involved are crucial.
The investigators hypothesise that a better knowledge of Thymoglobulin PK and its covariates would help to individualise dosage regimen and would improve clinical outcomes, such as GvHD and immune reconstitution.
The investigators aim to build a population PK model of Thymoglobulin in order to study PK variability and its covariates. This model will help in optimizing dosage regimen in an individually way.

Start Date25 Sep 2023

Sponsor / Collaborator

Hospices Civils de Lyon

NCT05917405 / RecruitingPhase 2IIT

FLUCLORIC: Randomized Multicentric Phase III Study Comparing the Efficacy of 2 Reduced Intensity Conditioning Regimens (Clofarabine/Busulfan vs Fludarabine/Busulfan) in Adults With AML and Eligible to Allogeneic Stem Cell Transplantation

Relapse remains the main cause of death in patients with myeloid malignancies, especially after an allotransplant. Using drugs with higher anti-leukemic activity as part of the conditioning regimen is one of the strategies to decrease relapse incidence in this population. Retrospective studies have shown that clofarabine can achieve impressive results compared to the use of fludarabine in acute myeloid leukemia (AML) as part of the conditioning regimen. Confirming such results in a prospective manner would definitely establish the CloB2A2 as a superior reduced-intensity conditioning (RIC) regimen compared to the FB2A2 for AML patients.302 AML patients (151 in each arm) in complete remission at transplant will be included with the main objective to demonstrate a significant better 2-year overall survival for CloB2A2 cases (70% vs 55%). A cost-utility analysis and a cost-effectiveness analysis will be also performed as well as an assessment of the quality of life after transplant. Clofarabine will be furnished to all centers. The duration of the study will be 5 years with 3 years of inclusion and 2 years of follow-up for each patient.

Start Date14 Sep 2023

Sponsor / Collaborator

Nantes University Hospital

100 Clinical Results associated with Anti-thymocyte Globulin (Rabbit)

100 Translational Medicine associated with Anti-thymocyte Globulin (Rabbit)

100 Patents (Medical) associated with Anti-thymocyte Globulin (Rabbit)

2,882

Literatures (Medical) associated with Anti-thymocyte Globulin (Rabbit)

31 Dec 2024·RENAL FAILURE

Cumulative rabbit anti-human thymocyte globulin dose to recipient weight during the peri-operative period is an independent risk factor for early postoperative urinary tract infection after kidney transplantation

Article

Author: Wang, Ziyu ; Cao, Yanwei ; Wang, Hongyang ; Li, Shujuan ; Dong, Zhen

Anti-human thymocyte globulin-Fresenius (ATG-F) is frequently utilized to achieve successful induction for kidney transplantation recipients. This study aimed to examine the association between the ATG-F dose-to-recipient-weight ratio (ADR) and the risk of developing urinary tract infections (UTIs) following kidney transplantation. Data of kidney transplant recipients who underwent ATG-F-induction peri-operatively in a medical center were retrospectively collected, and the incidence of UTIs during the first postoperative year was also recorded. The risk of UTI associated with ADR was analyzed, and receiver operating characteristic curves were drawn to determine the optimal ADR, followed by Cox regression models. In total, 131 recipients were included, with an UTI incidence of 19.08% and a mean interval of 3.08 months. The optimal ADR was 6.34, involving 41 and 90 patients in the low ADR and high ADR groups, respectively. The UTI-free rate in the low ADR group was significantly higher than that in the high ADR group (p = 0.007). Cox regression analysis indicated that a high ADR independently increased the risk of UTI following kidney transplantation (hazard ratio: 5.306, 95% confidence interval: 1.243-22.660, p = 0.024). There was no significant difference in rejection rate between the high ADR and low ADR groups. In conclusion, a high ADR increased the incidence of early postoperative UTI among kidney transplant recipients.

10 Dec 2024·Blood Advances

Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany

Article

Author: Amann, Elisa Maria ; Edinger, Matthias ; Bethge, Wolfgang ; Beyersmann, Jan ; Zeiser, Robert ; Schetelig, Johannes ; Labuhn, Svenja ; Franke, Georg-Nikolaus ; Bug, Gesine ; Eder, Matthias ; Schmid-Möglich, Amelie ; Neuchel, Christine ; Fürst, Daniel ; Ringhoffer, Mark ; Schrezenmeier, Hubert ; Schröder, Thomas ; Kröger, Nicolaus ; Stelljes, Matthias ; Teschner, Daniel ; Dreger, Peter ; Mytilineos, Joannis ; Arslan, Aysenur ; Sala, Elisa ; Schmeller, Sandra

Abstract:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10/10 MUDs with antithymocyte globulin (ATG)–based regimens (n = 7050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n = 487) in adult patients with hematologic malignancies between 2010 and 2020. Cox proportional hazard-and competing risks regression models were formed to compare the outcomes. Overall survival (OS), Disease-free survival (DFS), and graft-versus-host disease (GVHD)–free and relapse-free survival (GRFS) were superior for 10/10 MUDs (OS [hazard ratio (HR), 1.27; 95% confidence interval (CI), 1.10-1.47; P = .001]; DFS [HR, 1.17; CI, 1.02-1.34; P = .022]; GRFS [HR, 1.34; CI, 1.19-1.50; P < .001]). The risk of acute GVHD (aGVHD) grade 2 to 4, aGVHD grade 3 to 4, and chronic GVHD (cGVHD) was higher in the PT-CY Haplo group than the 10/10 MUD group (aGVHD grade 2-4 [HR, 1.46; CI, 1.25-1.71; P < .001]; aGVHD grade 3-4 [HR, 1.74; CI, 1.37- 2.20; P < .001]; cGVHD [HR, 1.30; CI, 1.11-1.51; P = .001]). A lower incidence of relapse was observed in the PT-CY Haplo group (relapse: HR, 0.83; CI, 0.69-0.99; P = .038). Unrelated 10/10 matched transplantation with ATG leads to lower GVHD rates and improved survival rates compared with PT-CY Haplo transplantation in Germany.

10 Dec 2024·Blood Advances

Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy

Article

Author: Kapoor, Neena ; Jacobsohn, David A. ; Klein, Orly ; Anderson, Eric ; Long-Boyle, Janel R. ; Cho, Soohee ; Collier, Willem ; Flower, Allyson ; Lalefar, Nahal ; Pulsipher, Michael A. ; Talano, Julie-An ; Holbrook-Brown, Lucia ; Abdel-Azim, Hisham ; Dvorak, Christopher C. ; Bunin, Nancy ; Bertaina, Alice ; Higham, Christine S. ; Vatsayan, Anant ; Odinakachukwu, Maryanne C.

Abstract:

We hypothesized that the inferior disease-free survival (DFS) seen in older patients who underwent αβ-T-cell/CD19–depleted (AB-TCD) haploidentical hematopoietic cell transplantation (HCT) for hematologic malignancies is caused by excessive exposure to rabbit antithymocyte globulin (rATG; Thymoglobulin). Between 2015 and 2023, 163 patients with a median age of 13 years (range, 0.4-27.4) underwent AB-TCD haploidentical HCT for the treatment of acute lymphoblastic leukemia (n = 98), acute myeloid leukemia/myelodysplastic syndrome (n = 49), or other malignancies (n = 16) at 9 centers in 2 prospective trials. Exposures to rATG before and after HCT were predicted using a validated pharmacokinetic model. Receiver operating characteristic curves were used to identify the optimal target windows for rATG exposure in terms of outcomes. We identified 4 quadrants of rATG exposure, namely quadrant 1 (n = 52) with a high pre-HCT area under curve (AUC; ≥50 arbitrary units [AU] per day per milliliter) and a low post-HCT AUC (<12 AU per day per liter); quadrant 2 (n = 47) with a low pre- and post-HCT AUC; quadrant 3 (n = 13) with a low pre-HCT and a high post-HCT AUC; and quadrant 4 (n = 51) with a high pre- and post-HCT AUC. Quadrant 1 had a 3-year DFS of 86.5%, quadrant 2 had a DFS of 64.6%, quadrant 3 had a DFS of 32.9%, and for quadrant 4 it was 48.2%. An adjusted regression analysis demonstrated additional factors that were associated with an increased hazard for worse DFS, namely minimal residual disease (MRD) positivity and cytomegalovirus (CMV) R+/D− serostatus. Nonoptimal rATG exposure exhibited the strongest effect in unadjusted and adjusted (MRD status or CMV serostatus) analyses. High exposure to rATG after HCT was associated with inferior DFS following AB-TCD haploidentical HCT for pediatric patients with hematologic malignancies. Model-based dosing of rATG to achieve optimal exposure may improve DFS. These trials were registered at www.ClinicalTrials.gov as #NCT02646839 and #NCT04337515.

News (Medical) associated with Anti-thymocyte Globulin (Rabbit)

21 Nov 2024

·endpts.com

Samsung Bio's new $668M client; Sanofi expands a factory in France

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has secured a number of manufacturing deals worth a total of $668 million with an unnamed European pharma client, the CDMO said Tuesday. The deals expire in 2031. Sanofi is investing €40 million ($42.1 million) to expand its bioproduction facility in Lyon, France, the company said Friday. In particular, €25 million ($26.3 million) will be used to make the antibody for Thymoglobulin and €15 million ($15.7 million) to make monoclonal antibodies for type 1 diabetes clinical-stage therapies. The UK regulatory agency MHRA has appointed University of Oxford professor Anthony Harnden as its new chair, according to a Tuesday release. Harnden replaces Stephen Lightfoot, who stepped down in April 2023. LIfT BioSciences has launched a new subsidiary called Eolaíocht Bhitheach LIfT Teoranta, which will operate from Galway, Ireland, the company said Monday. The subsidiary will collaborate with the University of Galway and medical tech manufacturer HookeBio to provide manufacturing and clinical services. Lonza has manufactured its first batch of drug products at its mammalian manufacturing facility in Portsmouth, NH, the company said Wednesday. Convergent Therapeutics has received its first shipment of the radioisotope actinium-225 from Cardinal Health to make its Phase 1/2 prostate cancer radiopharmaceutical, according to a Monday release. Meiji Seika Pharma is investing in the CDMO and mRNA vaccines company Arcalis to improve its supply of mRNA vaccines in Japan, according to a Thursday release. Arcalis will make the API for Meiji’s Covid-19 vaccine. No financial details were disclosed. India-based Unexo Life Sciences was handed an FDA warning letter published Tuesday. It outlined two key issues: failure to produce certain batch record data and dirty air conditioner vents above drug production areas. The White House published a report , dubbed Building a Vibrant Domestic Biomanufacturing Ecosystem, on Friday. It states that the US needs more infrastructure and technology to produce drugs domestically and outlines 11 actions that policymakers should consider to improve manufacturing.

VaccinemRNAExecutive Change

19 Nov 2024

·www.pharmamanufacturing.com

Sanofi invests $42M in Lyon for drug production

Sanofi has announced a €40 million investment in its Lyon Gerland bioproduction site, enhancing its capabilities in immunology-focused drug production. The investment supports the production of Thymoglobulin, used in transplantation, and localizes the manufacturing of TZIELD, a type 1 diabetes treatment, to France. Of the total investment, €25 million will fund the development of a second-generation polyclonal antibody for transplant patients, increasing production capacity and improving environmental sustainability. An additional €15 million will be allocated to producing monoclonal antibodies for type 1 diabetes treatment, previously manufactured outside the EU. Modernization efforts at the Lyon site began in mid-2024, with the first industrial batches of the updated polyclonal antibody expected in 2025 and commercial availability in 2027. Production of the existing treatment continues alongside these upgrades. Similarly, production of the immunomodulatory type 1 diabetes treatment will begin in late 2025, targeting market availability in 2027.

07 Nov 2024

·www.prnewswire.com

Fosun Attends CIIE for the Seventh Time - Guo Guangchang: Confident that China's High-Level Openness is a Historical Opportunity

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- On November 5, the 7th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center in Shanghai. As a seven-time attendee of the CIIE, Fosun showcased the latest achievements in innovation and global operations at its Fosun Pharma booth in Hall 7.1, featuring cutting-edge medical devices and innovative pharmaceuticals that made their debut in China. Guo Guangchang, Chairman of Fosun International, remarked, "Over the past seven years, CIIE has improved every year, becoming a window for China to build a new development framework, a platform for high-level openness, and an international public product for global sharing. Fosun has been a participant, witness, and beneficiary of the CIIE. Leveraging the CIIE platform, our long-term innovations have continually been put into practice, transforming many 'exhibits' into 'products', and converting many overseas partners from 'exhibitors' into 'investors'. This year, we continue to showcase our latest achievements in integrated innovation in the medical device and health sector, including several 'world's firsts' and 'China's firsts'. We firmly believe that China remains a significant opportunity for global development. Together with more overseas companies and global partners, we will promote more cutting-edge innovations to take root in China, moving forward and achieving mutual success on the grand stage of the CIIE." Stars of CIIE Taking Root, Transforming Ion from "Exhibit" to "Product" Healthcare is one of Fosun's main businesses. With CIIE's "spillover effect," several star products from Fosun, supported by the CIIE "accelerator" effect, have successfully entered the market to serve Chinese patients, transforming from "exhibits" into "products". This year, following the popular da Vinci Surgical System, the Ion Robotic Bronchoscopy made its CIIE debut after receiving domestic approval. Since its first appearance at the CIIE in 2019, Ion caught the attention of visitors. By the end of 2022, Ion entered the National Medical Products Administration's 'Green Channel' for innovative products and gained approval in March 2024, with the first commercial application completed in September. Lung cancer is considered the leading cause of cancer deaths, with 1.06 million new cases in China in 2022. The five-year survival rate is only 19.7%, and bronchoscopy is a key diagnostic tool for early lung cancer detection. The Ion bronchoscopy navigation control system offers innovative features for precise, convenient clinical diagnosis, providing new options for patients. By the third quarter of this year, 736 Ion systems had been installed globally, with over 150,000 Ion procedures performed. Outside the CIIE exhibition hall, Fosun is accelerating the localization of advanced medical devices. In June this year, Intuitive Fosun's headquarter industrial base was launched in Shanghai, marking Intuitive's largest R&D, production, and training center in the Asia-Pacific region. At this base, in addition to the Ion shape-sensing bronchoscopy control system, advanced products and core components, including the da Vinci surgical robot, are gradually achieving "Made in China, joint R&D, and global sales." Accelerating Integrated Innovation to Lead in Neurological Disease Treatment Transformation Fosun has long committed to investing in cutting-edge areas of healthcare, fostering a continuous stream of breakthrough "solid achievements" through an open innovation ecosystem involving independent R&D, collaborative development, licensing, and industry investment. These innovations are continually transformed into new drivers of growth. At this year's CIIE, Fosun introduced several latest products that are leading industry transformation. In the field of neurological disease treatment, especially for conditions like essential tremor and Parkinson's disease, patients have long faced challenges with unmet clinical needs. Traditional drug and surgical treatments often have limitations, but advancements in non-invasive treatment technologies have brought new hope to these patients. Fosun has actively responded to this unmet clinical need. At this year's CIIE, the new V2 model of the CNS (Central Nervous System) innovative treatment technology, the V2 model of "Exablate Neuro FUS system" made its debut in China, generating high expectations within the industry. This new model has already received CE certification in Europe and FDA approval in the United States and submitted a registration application to China's National Medical Products Administration in 2024. The V2 model's innovation lies in providing a non-invasive surgical solution for clinically drug-resistant essential tremor and tremor-dominant Parkinson's disease, while also being compatible with a broader range of MRI models, further enhancing the accessibility of this technology. Last year, Fosun, in partnership with Insightec, showcased the "Exablate Neuro" at CIIE, drawing much attention and continuous interest in collaboration. Leveraging the CIIE's "spillover effect", Fosun Pharma and Insightec established a joint venture, Fosun-Insightec, in February this year. The venture is focused on the marketing and developing clinical efforts of Exablate Neuro FUS system in improving the lives of patient living with essential tremor and Parkinson's disease, working to help them regain their quality life and wellbeing. Focusing on innovating to meet real customer needs is a core methodology for Fosun. Data shows that Fosun has made long-term investments in technological innovation, with an investment of RMB 3.5 billion in the first half of this year. Connecting Globally to Enhance Accessibility of Innovative Drugs, Benefiting more Patients Leveraging the CIIE's openness, Fosun also presented innovative products focused on solid tumors, hematological tumors, and immune-inflammatory conditions. Fosun's seven-year journey at CIIE has facilitated the introductions of global products and enabled the export of local innovations to benefit more patients worldwide. In 2017, Fosun introduced China's first CAR-T cell therapy product, Yi Kai Da (ejilunsai injection). Since then, by continuously participating in the CIIE, Fosun has enabled the public to gain an in-depth understanding of this advanced therapy. At this year's CIIE, Fosun highlighted Yi Kai Da's latest developments in the "accessibility and treatability" in lymphoma treatment. Yi Kai Da is now included in over 110 urban customized commercial health insurances and more than 80 commercial insurances, created a new path of payment mode for patients; and over 170 high-standard treatment centers across 28 regions in China providing treatments for over 900 lymphoma patients, achieving revolutionary innovative breakthroughs for cancer care. As a global company rooted in China, Fosun has an extensive industrial presence in over 35 countries and regions worldwide, with robust global R&D capabilities and impressive progress. This year, Fosun also showcased several innovative products, including the world's first and only dual-channel fixed-dose combination oral formulation, Akynzeo® oral (Netupitant and Palonosetron hydrochloride), which blocks both NK-1 and 5-HT3 receptors; the immunoglobulin Thymoglobulin® for improving transplant patient outcomes; the world's first oral targeted medication for psoriasis, Otezla® (apremilast tablets); a new third-generation COMT inhibitor Ongentys® (Opicapone) for managing symptom fluctuations in adult Parkinson's disease patients; and Parsabiv® (Etelcalcetide Hydrochloride Injection), the only peptide-based calcimimetic for treating secondary hyperparathyroidism in adult dialysis patients with chronic kidney disease. Guo Guangchang concluded, "Participating in CIIE has been a top priority for Fosun for seven consecutive years. We have witnessed CIIE become a crucial platform for global companies to share in China's development opportunities and deepened our global partnerships through this platform. We believe the CIIE stage will continue to expand, and Fosun's journey of innovation and globalization will grow broader." SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalImmunotherapy

100 Deals associated with Anti-thymocyte Globulin (Rabbit)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Graft Rejection	JP	Sanofi KK	22 Apr 2011
Bacterial Infections	AU	Sanofi-Aventis Australia Pty Ltd.	18 Jul 2008
Graft vs Host Disease	JP	Sanofi KK	16 Jul 2008
Anemia, Aplastic	KR	Sanofi-Aventis Korea Co., Ltd.	19 Jan 1993
Cardiac transplant rejection	KR	Sanofi-Aventis Korea Co., Ltd.	19 Jan 1993
Renal transplant rejection	KR	Sanofi-Aventis Korea Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Death, Sudden, Cardiac	Phase 3	GB	Genzyme Corp.	01 Jan 2011
Reperfusion Injury	Phase 3	GB	Genzyme Corp.	01 Jan 2011
Chronic graft-versus-host disease	Phase 3	CA	Genzyme Corp.	01 Apr 2010
Leukemia	Phase 3	CA	Genzyme Corp.	01 Apr 2010
Lung transplant rejection	Phase 3	US	Genzyme Corp.	01 Jan 2006
Primary Graft Dysfunction	Phase 3	US	Genzyme Corp.	01 Jan 2006
Diabetes Mellitus, Type 1	Phase 2	US	Genzyme Corp.	01 Apr 2010
Kidney Failure, Chronic	Phase 2	US	Sanofi	01 Mar 2010
Hematopoietic stem cell transplantation	Phase 2	US	Genzyme Corp.	01 Jan 2009
Acute Myeloid Leukemia	Phase 2	US	Genzyme Corp.	21 Jul 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02582775 (CTgov)	Phase 2	Epidermolysis Bullosa	17	Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm B)	oakzwxoabr(ltqnytuxmv) = xglrajytbs camiubsato (oknxhebwot, ezrakyrznc - vzpiouyelf) View more	-	19 Sep 2024
NCT02582775 (CTgov)	Phase 2	Epidermolysis Bullosa	17	Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm E)	oakzwxoabr(ltqnytuxmv) = hcwcwramba camiubsato (oknxhebwot, ohfrmgqztm - fhomciiwyg) View more	-	19 Sep 2024
EHA2024	Not Applicable	Hematologic Neoplasms	211	ATG-Genzyme (ATG-G) ≤6 mg/kg	zdqrblkjqu(vhlsrdvmgd) = udxfibzqor aknwfpegqa (baduopwiuv, 40.8% - 56.3) View more	-	14 May 2024
EHA2024	Not Applicable	Hematologic Neoplasms	211	ATG-Fresenius (ATG-F) 20mg/kg	jdqolsyawy(ohxjjokckq) = lkptryxpxw jcsrzygjzh (ojgpmnubfy, 15.7% - 26.8) View more	-	14 May 2024
Tandem Meetings ASTCT and CIBMTR2024	Not Applicable	Anemia, Sickle Cell	28	Thiotepa, Fludarabine, Thymoglobulin, Low Dose Cyclophosphamide, 200 Cgy TBI and Post-Transplant Cyclophosphamide	njpyizhczc(qljxllaqva) = ztldwribvi cgfamcnmyx (hveomzfqsi ) View more	Positive	01 Feb 2024
Tandem Meetings ASTCT and CIBMTR2024	Not Applicable	Hematologic Neoplasms	-	Rabbit Antithymocyte (High pre-HCT AUC and low post-HCT)	msiuiyalfb(ezagcosclv) = chzuvubyyq fzlcbfepnk (rpmutswbjr, 76.3 - 96.7)	-	01 Feb 2024
Tandem Meetings ASTCT and CIBMTR2024	Not Applicable	Hematologic Neoplasms	-	Rabbit Antithymocyte (Low pre-HCT and post-HCT AUCs)	msiuiyalfb(ezagcosclv) = pkvumptjqi fzlcbfepnk (rpmutswbjr, 49.1 - 80.1)	-	01 Feb 2024
Pubmed \| Diabetes Care	Not Applicable	Diabetes Mellitus, Noninsulin-Dependent, 1	6	Low-dose Antithymocyte Globulin (ATG) 2.5 mg/kg	gsnmrhdisd(gqofhwidvj) = pflgplvudk tsysvbqteo (ysspsuhbid ) View more	Positive	01 Feb 2024
NCT02441803 (CTgov)	Phase 2	Acute Myeloid Leukemia	11	Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Decitabine+cytarabine+Idarubicin (Matched Sibling Donor Group)	kdvqajngbs(ywfqlimvuf) = unlvrdtcqw edbbjigihp (lqgrggqvbz, jhhdbzmfsh - qyendfzwyu) View more	-	17 Jan 2024
NCT02441803 (CTgov)	Phase 2	Acute Myeloid Leukemia	11	Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Decitabine+Tacrolimus+mycophenolate mofetil+cytarabine+Idarubicin (Haploidentical Donor Group)	kdvqajngbs(ywfqlimvuf) = djiustixnn edbbjigihp (lqgrggqvbz, eohneusrgg - flgjochktv) View more	-	17 Jan 2024
NCT01850108 (CTgov)	Not Applicable	Anemia, Sickle Cell	26	Bone marrow transplantation+Mesna+Fludarabine+Thymoglobulin+Sirolimus+Mycophenolate mofetil (MMF)+Cyclophosphamide (CTX)	avtebehqbl(gwngbqghft) = aobwysawlo pkxvwafqdt (arlxusajom, qiozswwhuv - xbqiydwlbh) View more	-	10 Jan 2024
NCT02464878 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	2	Islet Transplantation+Thymoglobulin+Basiliximab+Alpha 1-Antitrypsin+Etanercept	ilxdjwgkon(rwtohxncav) = sdovweoort petysxuauy (pfjhwkknei, dmmfgpzjss - bnuayqrizb) View more	-	22 Dec 2023
ASH2023	Not Applicable	Refractory Severe Aplastic Anemia	68	Haplo-SCT with fTBI 600 cGy/Flu/ATG-5	dxxuaabzii(siuopmsxgp) = zwrlksiupr wbqijmgpug (toelorzwah ) View more	-	11 Dec 2023
PTCTC ONC1401 (ASH2023)	Not Applicable	Neoplasms	134	rATG	jvmlnaqhiz(xwgljkqida) = mpmhpzguvb meuyqapjlc (hbvmnrwvlg, 50.2 - 67.8) View more	-	10 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Anti-thymocyte Globulin (Rabbit)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation